Beta Drugs Limited has informed the Exchange about submission of Revised Update -Acquisition of 66.09% Stake by Beta Drugs Limited in Nivian Lifesciences Private Limited.
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beta Drugs Limited is acquiring a 66.09% stake in Nivian Lifesciences Private Limited for INR 69.4 Crores, valuing Nivian at INR 105 Crores. Nivian is a branded formulations company focused on In-Vitro Fertilisation (IVF) therapy, one of the fastest-growing pharma segments in India growing at ~20% CAGR with a total market size of INR 1,500-1,700 Crores. Founded in 2019 by Nilesh Auti (ex-Bharat Serums), Nivian reported net sales of INR 30.30 Crores for 9M ended Dec'25 and is expected to close FY26 at ~INR 43 Crores. This is a corrected version of an earlier filing dated 10.01.2026 that contained a typing error. The founder will continue to lead Nivian and remain invested.
Positive for Beta Drugs shareholders — the deal gives the company a strong foothold in the fast-growing IVF/women's health segment, complementing its existing complex formulations business in oncology and cosmetology. The high-growth target (Nivian) could boost Beta's revenue and margins over the medium term, though integration risks and the cash outflow of INR 69.4 Crores should be monitored.